Home » Infectious Disease
You are browsing entries filed in “Infectious Disease”
By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human ServicesMay 18th was HIV Vaccine Awareness Day, and we wanted to remind you of several posts we did last week on that subject. On Friday, we featured a guest post, Moving Forward on HIV Vaccine Awareness Day, by Dr. Nelson Michael, director of the U.S. Military HIV Research Program
To the Most Vulnerable, The Least Reward: While the immense accomplishments of the President’s Emergency Plan For AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the governments that have worked with them have seen drops in HIV incidence as high as 73 percent in southern Africa, the benefits of these successes (Read more…)
A new diagnostic test strip to rapidly detect lymphatic filariasis – also known as elephantiasis – in human blood has significant advantages over the standard card test that has been used for more than a decade to map, monitor and assess the success of the massive global campaign to eliminate the disease. via allAfrica.com: Africa: [...]
Gaps in the healthcare system in the Democratic Republic of Congo (DRC) are hampering the fight against malaria, a leading killer of children, say experts. via allAfrica.com: Congo-Kinshasa: Malaria Overstretching Healthcare in DRC (Page 1 of 3).
Whooping cough has exploded in the United States and some other developed countries in recent decades, and many experts suspect ineffective childhood vaccines for the alarming resurgence. via Leading explanations for whooping cough’s resurgence don’t stand up to scrutiny.
By Malaria Journal
Background: Assaying for the parasitic lactate dehydrogenase (pLDH) is widely used as a rapid diagnostic test (RDT), but the efficacy of its serological effectiveness in diagnosis, that is antibody detection ability, is not known. The genetic variation of Korean isolates was analysed, and recombinant protein pLDH was evaluated as a serodiagnostic antigen for the detection of Plasmodium vivax malaria. Methods: Genomic DNA was purified, and the pLDH gene of P. vivax was amplified from blood samples from 20 patients. The samples came from five epidemic areas: Bucheon-si, Gimpo-si, and Paju-si of Gyeonggi Province, Gangwha-gun of Incheon metropolitan city, and Cheorwon-gun of Gangwon Province, South Korea, from 2010 to 2011.
By Malaria Journal
Background: Malaria rapid diagnostic tests (RDTs) are commonly used in Medecins Sans Frontieres (MSF) programmes to detect acute malaria infection. Programmes in regions with both Plasmodium falciparum and non-falciparum malaria (i.e. Plasmodium ovale, Plasmodium malariae and Plasmodium vivax) use a three-band P. falciparum/Pan test such as the SD Bioline Malaria Ag P.f/Pan 05FK60 (Standard Diagnostics, Kyonggi, Republic of Korea), hereafter referred to as SD 05FK60, as used by the MSF-Holland clinics in Rakhine state, Myanmar. In spite of published reports of generally good test performance, medical and paramedical staff on the ground often doubt the diagnostic accuracy of these RDTs.
By Richard Klein, Patient Liaison Program Director, Office of Health and Constituent Affairs, Food and Drug AdministrationThe Food and Drug Administration (FDA) wants to talk to people living with HIV (PLWH) and HIV/AIDS advocates. On June 14, under its Patient-Focused Drug Development initiative, FDA will ask PLWH to join an open public discussion about: the impact of HIV on daily your life, experience with currently available therapies to treat HIV, your views on issues related to HIV cure research, including perceived benefits and acceptable risk for participating in HIV cure research, and how best to ensure clear communication of potential benefits and possible risks through informed consent. This discussion is intended to help improve drug development and treatment, and get patients’ perspective into HIV cure research. The meeting takes place on June 14, 2013, from 9:30 AM – 5:30 PM at FDA’s White Oak Campus, located at: 10903 New Hampshire Avenue Building 31, (in The Great Room) Silver Spring, Maryland 20993 There is no cost to attend, but if you would like to attend, please register by June 5.
By End the Neglect
; At the recent “Uniting to Combat NTDs: Translating the London Declaration into Action,” we had a chance to catch up with David Addiss, the director of Children Without Worms (CWW). CWW is a partnership between Johnson & Johnson, GlaxoSmithKline, and the Task Force for Global Health to support the treatment and prevention of infection
By Sara Gorman
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as staphylococci (Staphylococcus aureus). via Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria.
Two new medical discoveries are raising hopes of containing malaria – the mosquito-borne parasitic disease that each year infects more than 200 million people and claims an estimated 660 thousand lives. Meantime, the World Health Organization is warning about dire consequences if a drug-resistant form of malaria spreads beyond southeast Asia. via Scientists Race to [...]
By Malaria Journal
Background: Plasmodium vivax continues to be the most widely distributed malarial parasite species in tropical and sub-tropical areas, causing high morbidity indices around the world. Better understanding of the proteins used by the parasite during the invasion of red blood cells is required to obtain an effective vaccine against this disease. This study describes characterizing the P. vivax asparagine-rich protein (PvARP) and examines its antigenicity in natural infection. Methods: The target gene in the study was selected according to a previous in silico analysis using profile hidden Markov models which identified P.
By AIDS.gov Cross-posted from NIAID, NIHThe implementation of scientifically proven HIV prevention strategies is helping to reduce the number of new infections — the annual HIV infection rate globally fell by 22 percent from 2001 to 2011 — but a great deal more must be done. Significant scale-up of proven HIV prevention strategies coupled with the discovery of new HIV treatment and prevention interventions are needed to achieve an end to the global HIV/AIDS pandemic. A safe, effective and durable HIV vaccine is an essential cornerstone to the long-term strategy to achieve this goal. Developing a safe and effective HIV vaccine has been a long and difficult process largely because HIV has proven to be an especially tough target. Recent developments with the HVTN 505 clinical trial and analyses from the HVTN 503 “Phambili” vaccine study have been disappointing, but they also provided clear answers about investigational vaccine strategies that, ultimately, were not effective.
By Howard K. Koh, M.D., M.P.H., Assistant Secretary for Health, U.S. Department of Health and Human ServicesDr. Howard Koh As we celebrate Asian Americans and Pacific Islanders (AAPI) Heritage Month and the many accomplishments of AAPIs, we also want to recognize that these communities still face many barriers to health and health care, including HIV/AIDS. To recognize these challenges, May 19th has been designated as the National Asian & Pacific Islander HIV/AIDS Awareness Day.